---
document_datetime: 2023-09-21 17:03:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/emadine-epar-procedural-steps-taken-authorisation_en.pdf
document_name: emadine-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4029665
conversion_datetime: 2025-12-21 22:31:13.535374
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Alcon  Laboratories  (UK)  Ltd  submitted  on  26  November  1997  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Emadine, through the centralised procedure. After agreement by the CPMP on 20 June 1996, this medicinal product was referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr E Abadie

Co-Rapporteur:

Mr H Hovgaard, replaced by Dr G Jensen

## 2. Steps taken for the assessment of the product

- The procedure started on 17 December 1997
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  2  March 1998.  The  Co-rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 4 March 1998
- During  the  meeting  on  20  -  22  April  1998  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the Company on 23 April 1998.
- The company submitted the responses to the consolidated list of questions on 13 July 1998
- The Rapporteur circulated the joint response assessment report on the company's responses to the  list  of  questions  to  all  CPMP  Members  on  1  September  1998.  Comments  from  Member States were received by 10 September 1998.
- During the  meeting  on  15-17  September 1998,  the  CPMP  discussed  a  number  of  unresolved issues relating to efficacy and safety of the product and prepared a list of two outstanding issues relating to proof of efficacy, to be addressed by the applicant at an oral presentation. This was communicated to the company on 16 September 1998.
- During  the  meeting  on  20-22  October  1998  the  company  gave  an  oral  presentation  on  the outstanding issues, on 20 October 1998.
- The company submitted a letter of undertaking dated 20 October 1998, to provide information as follow-up measures.
- During the meeting on 20-22 October 1998 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Emadine on 22 October 1998.
- The CPMP opinions were  forwarded in all official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 27 January 1999.